To date, numerous missense mutations have been linked to PD pathogenesis, including R1441C, R1441G, R1441H, Y1699C, G2019S, and I2020T, and as such LRRK2 has been a popular choice of target for therapeutic modulation [53,54]. This evidence concerns the gene LRRK2 and Parkinson disease.